Trial Profile
A Double-blind, Placebo-controlled Study to Assess the Effects of Inhaled PC945 in the Treatment of Culture-positive Aspergillus or Candida Fungal Bronchitis in Subjects With Moderate to Severe Asthma or Other Chronic Respiratory Diseases
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Opelconazole (Primary)
- Indications Aspergillosis; Asthma; Bronchitis; Candidiasis
- Focus Therapeutic Use
- Sponsors Pulmocide
- 10 Jun 2020 Status changed from recruiting to discontinued.
- 10 Apr 2019 Planned End Date changed from 30 Jun 2019 to 28 Feb 2020.
- 10 Apr 2019 Planned primary completion date changed from 30 Apr 2019 to 31 Dec 2019.